CARG — what changed in the latest 10-Q
A section-by-section comparison of CARG's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-06 vs the prior 10-Q · 2026-05-07
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +33 | −20 | ~22 | 54 |
| Market risk (Item 3) | Text added/removed | 0 | 0 | ~5 | 2 |
| Controls & procedures | No paragraph-level changes | 0 | 0 | 0 | 3 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Risk factors | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Other information | Text added/removed | +3 | 0 | ~2 | 3 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-06
For the three months ended June 30, 2026, we generated revenue of $251.0 million, a 13% increase from $222.0 million of revenue for the three months ended June 30, 2025. For the three months ended June 30, 2026, we generated net income from continuing operations of $49.2 million and Adjusted EBITDA …
Product, technology, and development expense increased $4.4 million, or 13%, in the three months ended June 30, 2026, compared to the three months ended June 30, 2025. The increase was due primarily to a $2.1 million increase in employee-related expenses due primarily to headcount and merit increase…
Impairment expense remained relatively flat in the three months ended June 30, 2026, compared to the three months ended June 30, 2025.
Provision for income taxes remained relatively flat in the three months ended June 30, 2026, compared to the three months ended June 30, 2025.
Revenue increased $60.3 million, or 14%, in the six months ended June 30, 2026, compared to the six months ended June 30, 2025. The increase was due primarily to an increase in dealer subscription revenue as a result of growth in QARSD, which was driven by signing on new dealers at market rates, and…
Text removed vs the prior filing · source: 10-Q · 2026-05-07
For the three months ended March 31, 2026, we generated revenue of $243.6 million, a 15% increase from $212.2 million of revenue for the three months ended March 31, 2025.
Product, technology, and development expense increased $2.6 million, or 8%, in the three months ended March 31, 2026, compared to the three months ended March 31, 2025. The increase was due primarily to a $1.6 million increase in consulting expense and a $1.5 million increase in personnel expenses d…
Impairment expense increased $19.2 million in the three months ended March 31, 2026, compared to the three months ended March 31, 2025. The increase was due primarily to the impairment of the 121 First Street lease during the three months ended March 31, 2026. For further discussion of the lease imp…
Provision for income taxes changed $2.5 million in the three months ended March 31, 2026, compared to the three months ended March 31, 2025. The decrease was due primarily to decreased profitability resulting from the recording of the lease impairment expense.
As of March 31, 2026 and December 31, 2025, our principal sources of liquidity were cash and cash equivalents of $72.0 million and $190.5 million, respectively. As of March 31, 2026 and December 31, 2025, our borrowing capacity under the 2022 Revolver (as defined below) was $390.6 million.
Other information
Text added vs the prior filing · source: 10-Q · 2026-08-06
The Rule 10b5-1 trading arrangement includes the sale of up to 44,906 shares to be received upon future vesting of certain outstanding equity awards, net of any shares withheld by us to satisfy applicable taxes. The number of shares to be withheld, and thus the exact number of shares to be sold purs…
The Rule 10b5-1 trading arrangement was entered into among Hilary and Langley Steinert, acting jointly, and the Langley Steinert Irrevocable Family Trust dated June 21, 2024, or the Steinert Trust. Of the 1,493,200 shares to be sold pursuant to this Rule 10b5-1 trading arrangement, Hilary and Langle…
The Rule 10b5-1 trading arrangement permits transactions through February 26, 2027, subject to early termination for certain specified events set forth in the Rule 10b5-1 trading arrangement, or earlier if all transactions under the Rule 10b5-1 trading arrangement are completed.
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice